Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

Tivozanib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 11-03-2021 | FDA | News | Article
    approvalsWatch

    Tivozanib approved for US patients with refractory advanced RCC

    The objective response rate was also higher among tivozanib-treated participants, but overall survival was comparable between groups at the time of analysis.

    Author:
    Shreeya Nanda
  2. play
    19-02-2021 | ASCO GU 2021 | Conference coverage | Video

    TIVO-3 results point to tivozanib activity after RCC progression on axitinib

    Brian Rini describes an analysis of the TIVO-3 advanced renal cell carcinoma trial suggesting that tivozanib offers better outcomes than sorafenib even in patients who have previously received axitinib.

  3. 22-10-2019 | Renal cell carcinoma | News | Article

    Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

    Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

    Published in:
    ESMO Congress 2019; Barcelona, Spain: 27 September–1 October
  4. 20-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Tivozanib improves refractory advanced RCC outcomes

    The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.

    Published in:
    ASCO GU 2019; San Francisco, California, USA: 14–16 February
  5. 01-07-2019 | Renal cell carcinoma | News | Article

    Targeted therapy can benefit complex patients with advanced RCC

    . © 2019 Springer Healthcare part of the Springer Nature group JAMA Network Open 2019; 2 : e195806 JAMA Network Open 2019; 2 : e195815 See also: Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy Tivozanib improves refractory advanced RCC outcomes   Pembrolizumab-axitinib boosts untreated advanced RCC survival

    Published in:
    JAMA Network Open 2019; 2 : e195806 JAMA Network Open 2019; 2 : e195815
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.